<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097574</url>
  </required_header>
  <id_info>
    <org_study_id>NPO-13-01/ED-01</org_study_id>
    <nct_id>NCT04097574</nct_id>
  </id_info>
  <brief_title>Study of NPO-13 During Colonoscopy</brief_title>
  <official_title>Phase II Study of NPO-13 in Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety, efficacy and dose-response of NPO-13 in subjects with&#xD;
      moderate to severe colonic spasm during colonoscopy. An intraluminal spraying of NPO-13 dosed&#xD;
      up to twice into ascending or sigmoid colon. The colonic spasm will be assessed by an&#xD;
      independent committee using recorded video images. The study consists of a screening visit&#xD;
      window, 1-day treatment phase and 1-week follow-up phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Actual">March 26, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of No or Mild colonic spasm at the all sites of NPO-13 treatment</measure>
    <time_frame>3 minutes</time_frame>
    <description>The primary endpoint will be evaluated by third-party organization, using a four-grade scale: 1, No; 2, Mild; 3, Moderate; 4, Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of No or Mild colonic spasm at the each site of NPO-13 treatment</measure>
    <time_frame>3 minutes</time_frame>
    <description>The secondary endpoint will be evaluated by third-party organization, using a four-grade scale: 1, No; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in colonic spasm before and after treatment of NPO-13 treatment</measure>
    <time_frame>3 minutes</time_frame>
    <description>The evaluated colonic spasm grades will be converted into a numeric score, and difference between paired mean scores (before and after application, or 0.8% NPO-13, 1.6% NPO-13 and placebo) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to effect</measure>
    <time_frame>3 minutes</time_frame>
    <description>The onset of anti-spasmodic effect is the interval from the spray to the disappearance of the spasm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty of endoscopic observation</measure>
    <time_frame>3 minutes</time_frame>
    <description>The proportion of subjects in whom intracolonic examination will be evaluated by the investigator to be &quot;Very easy&quot; or &quot;Easy&quot;., using a four-grade scale: 1, Very easy; 2, Easy; 3, Difficult; 4, Hard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and Adverse drug reactions</measure>
    <time_frame>7 Â± 3 days</time_frame>
    <description>The subjects will be observed for 7 days after colonoscopy, and all adverse events and adverse drug reactions will be recorded and compared with the placebo group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Bowel Disease</condition>
  <arm_group>
    <arm_group_label>NPO-13 0.8%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPO-13 1.6%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPO-13 0%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPO-13: l-menthol</intervention_name>
    <description>20 mL/site</description>
    <arm_group_label>NPO-13 0%</arm_group_label>
    <arm_group_label>NPO-13 0.8%</arm_group_label>
    <arm_group_label>NPO-13 1.6%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are between 20 and 85 years at the time of consent&#xD;
&#xD;
          2. Patients who need colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of abdominal surgical treatment (including the laparoscopic&#xD;
             surgery) including the gynecology operation&#xD;
&#xD;
          2. Patients with contraindication to colonoscopy including the paralytic ileus&#xD;
&#xD;
          3. Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil&#xD;
             (mint oil)&#xD;
&#xD;
          4. Patient with contraindication to bowel cleansing preparation&#xD;
&#xD;
          5. Patient with contraindication to pain medicine and sedative medicine&#xD;
&#xD;
          6. Patient with contraindication to butylscopolamine bromide and glucagon&#xD;
&#xD;
          7. Patients on cancer treatment (chemotherapy or radiotherapy)&#xD;
&#xD;
          8. Patient with active inflammatory bowel disease or infectious enteritis&#xD;
&#xD;
          9. Patients who need sedative in colonoscopy&#xD;
&#xD;
         10. Patients who receives a therapeutic colonoscopy&#xD;
&#xD;
         11. Pregnant or lactating women, women of childbearing potential, or women who plan to&#xD;
             become pregnant during the study&#xD;
&#xD;
         12. Patients who have received other investigational drugs within four months before&#xD;
             consent or who are participating in other clinical studies&#xD;
&#xD;
         13. Patients otherwise ineligible for participation in the study in the investigator's or&#xD;
             coinvestigator's opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisatsugu Asada</last_name>
    <role>Study Chair</role>
    <affiliation>Nihon Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NPO-13 Trial Site 11</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 12</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 2</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 5</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 6</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 1</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 4</name>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 3</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 9</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 13</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 10</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 7</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NPO-13 Trial Site 8</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

